title: Paclitaxel-anthracycline combination chemotherapy in relapsing advanced ovarian cancer after platinum-based chemotherapy: a pilot study.
abstract: Despite high response rates with platinum-based front-line chemotherapy, the prognosis for advanced ovarian carcinoma (AOC) is poor. Salvage chemotherapy for recurrent AOC was of little benefit before paclitaxel as single-agent therapy showed appreciable efficacy. Anthracyclines are effective, but are not often part of first-line therapy. In this pilot study, we investigated the feasibility of an anthracycline plus paclitaxel combination therapy for recurrent AOC. Twenty-four patients received 150 mg/m2 paclitaxel on day 1, with either 50 mg/m2 doxorubicin on day 1 or 75 mg/m2 epirubicin on day 1 every 3 weeks. A 27% overall response rate was obtained. Myelosuppression was the major toxicity, but was manageable. No myocardiac toxicity was observed. We conclude that paclitaxel-anthracyclines is a promising salvage combination therapy in AOC that should be investigated further.
authors.affiliation: Department of Onco-Hematology, Hôpitaux Universitaires, Strasbourg, 67098, France.
authors.forename: J E
authors.initials: JE
authors.lastname: Kurtz
authors.forename: G
authors.initials: G
authors.lastname: Deplanque
authors.forename: B
authors.initials: B
authors.lastname: Duclos
authors.forename: F
authors.initials: F
authors.lastname: Eichler
authors.forename: C
authors.initials: C
authors.lastname: Giron
authors.forename: J M
authors.initials: JM
authors.lastname: Limacher
authors.forename: R
authors.initials: R
authors.lastname: Herbrecht
authors.forename: F
authors.initials: F
authors.lastname: Maloisel
authors.forename: F
authors.initials: F
authors.lastname: Oberling
authors.forename: J P
authors.initials: JP
authors.lastname: Bergerat
authors.forename: P
authors.initials: P
authors.lastname: Dufour
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D010865:Pilot Projects; D017671:Platinum Compounds / Q000627:therapeutic use; D012008:Recurrence; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D017671:Platinum Compounds; D017239:Paclitaxel